Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 1-2, 2006, Pages 128-133

  Šturm, Katja ^a   Levstik, Lea ^a   Demopoulos, Vassilis J ^b   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

ARIs; Biopharmaceutical classification system; Diabetes mellitus; Jejunum; Multidrug resistance transporters; P glycoprotein; Permeability

Indexed keywords

2,6 DIFLUORO 4 PYRROL 1 YL PHENOL DERIVATIVE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG PENETRATION; IN VITRO STUDY; IN VIVO STUDY; JEJUNUM; NONHUMAN; PRIORITY JOURNAL; RAT;

ALDEHYDE REDUCTASE; ALGORITHMS; ANIMALS; BIOLOGICAL AVAILABILITY; BUFFERS; CHEMISTRY, PHYSICAL; ENZYME INHIBITORS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; JEJUNUM; PERMEABILITY; PYRROLES; RATS; RHODANINE; THIAZOLIDINES;

EID: 33644896551     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.01.006     Document Type: Article

References (16)

1. Anders Lindhal, S.F., Ungell, A.L., Lennernäs, H., 2000. No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in rats. AAPS Pharmsci. 2(3) (article 26, http://www.pharmsci.org/ ).
2. V.J. Demopoulos, and E. Rekka Isomeric benzoylpyrroleacetic acids: some structural aspects for aldose reductase inhibitory and anti-inflammatory activities J. Pharm. Sci. 84 1995 79 82
3. T. Fujisawa, H. Ikegami, Y. Kawaguchi, K. Nojima, Y. Kawabata, M. Ono, M. Nishino, S. Noso, H. Taniguchi, M. Horiki, M. Itoi-Babaya, N. Babaya, K. Inoue, and T. Ogihata Common genetic basis between type 1 and 2 diabetes mellitus indicated by interview-based assessment of family history Diabetes Res. Clin. Pract. 66S 2004 S91 S95
4. N. Hotta, T. Toyota, K. Matsuoka, Y. Shigeta, R. Kikkawa, T. Kaneko, A. Takahashi, K. Sugimura, Y. Koike, J. Ishii, and N. Sakamoto Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy Diabetes Care 24 2001 1776 1782
5. B.F. Johnson, R.W. Nesto, M.A. Pfeifer, W.R. Slater, A.I. Vinik, D.A. Chyun, G. Law, F.J. Wackers, and L.H. Young Cardiac abnormalities in diabetic patients with neuropathy Diabetes care 27 2004 448 454
6. I. Legen, and A. Kristl D-glucose triggers multidrug resistance- associated protein (MRP)-mediated secretion of fluorescein across rat jejunum in vitro Pharm. Res. 21 2004 635 640
7. H. Lennerns Human intestinal permeability J. Pharm. Sci. 87 1998 403 410
8. S. Miyamoto Molecular modeling and structure-based drug discovery studies of aldose reductase inhibitors Chem. Bio. Inform. J. 2 2002 74 85
9. I. Nicolaou, and V.J. Demopoulos Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonezymatic irreversible modification of proteins from monosaccharides J. Med. Chem. 46 2003 417 426
10. I. Nicolaou, C. Zika, and V.J. Demopoulos [1-(3,5-difluoro-4- hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor J. Med. Chem. 47 2004 2706 2709
11. J.E. Polli, L.X. Yu, J.A. Cook, G.L. Amidon, R.T. Borchardt, B.A. Burnside, P.S. Burton, M.L. Chen, D.P. Conner, P.J. Faustino, A.A. Hawi, A.S. Hussain, H.N. Joshi, G. Kwei, V.H. Lee, L.J. Lesko, R.A. Lipper, A.E Loper, S.G. Nerurkar, J.W. Polli, R. Sanvorde, R.S. Taneja, C. Uppoor, S. Vattikonda, I. Wilding, and G. Zhang Commentary: summary workshop report: biopharmaceutics classification system - implementation challenges and extension opportunities J. Pharm. Sci. 93 2004 1375 1381
12. M. Sababi, O. Borga, and U. Hultkvist-Bengtsson The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats Eur. J. Pharm. Sci. 14 2001 21 27
13. U.S. Department of Health and Human Services, 2000. BP. Guidance for industry: waiver of in vitro bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biophar-maceutics classification system. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
14. N. Zaher, I. Nicolaou, and V.J. Demopoulos Pyrrolylbenzothiazole derivatives as aldose reductase inhibitors J. Enzyme Inhib. Med. Chem. 17 2002 131 135
15. D. Ziegler Polynevropathy in the diabetic patients-update on pathogenesis and management Nephrol. Dial. Transplant. 19 2004 2170 2175
16. C. Zika Synthesis of new heterocyclic chemotypes with putative pharmacotherapeutic potential for the threatment of depression and of the late onset diabetes mellitus complications. A biochemical and computational approach Fharmakeftiki 17 2004 89 90